vs
Side-by-side financial comparison of BALCHEM CORP (BCPC) and ENCORE CAPITAL GROUP INC (ECPG). Click either name above to swap in a different company.
ENCORE CAPITAL GROUP INC is the larger business by last-quarter revenue ($473.6M vs $263.6M, roughly 1.8× BALCHEM CORP). ENCORE CAPITAL GROUP INC runs the higher net margin — 16.2% vs 14.9%, a 1.3% gap on every dollar of revenue. On growth, ENCORE CAPITAL GROUP INC posted the faster year-over-year revenue change (78.3% vs 9.8%). Over the past eight quarters, ENCORE CAPITAL GROUP INC's revenue compounded faster (20.1% CAGR vs 4.9%).
Balchem Corp is a global specialty chemicals and nutritional ingredients provider that develops, manufactures and distributes application-specific products for human nutrition, animal health, pharmaceutical and industrial end markets, serving customers across North America, Europe and Asia Pacific.
Encore Capital Group, Inc. is a publicly traded debt buyer based in the United States. The company is headquartered in San Diego, and operates throughout the United States. The firm is a publicly traded NASDAQ Global Select company (ECPG), a component stock of the Russell 2000, the S&P SmallCap 600, and the Wilshire 4500.
BCPC vs ECPG — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $263.6M | $473.6M |
| Net Profit | $39.2M | $76.7M |
| Gross Margin | 35.6% | — |
| Operating Margin | 19.8% | 36.6% |
| Net Margin | 14.9% | 16.2% |
| Revenue YoY | 9.8% | 78.3% |
| Net Profit YoY | 16.8% | — |
| EPS (diluted) | $1.21 | $3.32 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $263.6M | $473.6M | ||
| Q3 25 | $267.6M | $460.4M | ||
| Q2 25 | $255.5M | $442.1M | ||
| Q1 25 | $250.5M | $392.8M | ||
| Q4 24 | $240.0M | $265.6M | ||
| Q3 24 | $239.9M | $367.1M | ||
| Q2 24 | $234.1M | $355.3M | ||
| Q1 24 | $239.7M | $328.4M |
| Q4 25 | $39.2M | $76.7M | ||
| Q3 25 | $40.3M | $74.7M | ||
| Q2 25 | $38.3M | $58.7M | ||
| Q1 25 | $37.1M | $46.8M | ||
| Q4 24 | $33.6M | — | ||
| Q3 24 | $33.8M | $30.6M | ||
| Q2 24 | $32.1M | $32.2M | ||
| Q1 24 | $29.0M | $23.2M |
| Q4 25 | 35.6% | — | ||
| Q3 25 | 35.7% | — | ||
| Q2 25 | 36.4% | — | ||
| Q1 25 | 35.2% | — | ||
| Q4 24 | 36.0% | — | ||
| Q3 24 | 35.6% | — | ||
| Q2 24 | 35.5% | — | ||
| Q1 24 | 34.0% | — |
| Q4 25 | 19.8% | 36.6% | ||
| Q3 25 | 20.4% | 37.6% | ||
| Q2 25 | 20.1% | 34.1% | ||
| Q1 25 | 20.4% | 32.9% | ||
| Q4 24 | 19.8% | — | ||
| Q3 24 | 20.0% | 28.9% | ||
| Q2 24 | 19.6% | 28.7% | ||
| Q1 24 | 17.4% | 25.5% |
| Q4 25 | 14.9% | 16.2% | ||
| Q3 25 | 15.1% | 16.2% | ||
| Q2 25 | 15.0% | 13.3% | ||
| Q1 25 | 14.8% | 11.9% | ||
| Q4 24 | 14.0% | — | ||
| Q3 24 | 14.1% | 8.3% | ||
| Q2 24 | 13.7% | 9.1% | ||
| Q1 24 | 12.1% | 7.1% |
| Q4 25 | $1.21 | $3.32 | ||
| Q3 25 | $1.24 | $3.17 | ||
| Q2 25 | $1.17 | $2.49 | ||
| Q1 25 | $1.13 | $1.93 | ||
| Q4 24 | $1.03 | — | ||
| Q3 24 | $1.03 | $1.26 | ||
| Q2 24 | $0.98 | $1.34 | ||
| Q1 24 | $0.89 | $0.95 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $74.6M | $156.8M |
| Total DebtLower is stronger | — | $4.0B |
| Stockholders' EquityBook value | $1.3B | $976.8M |
| Total Assets | $1.7B | $5.3B |
| Debt / EquityLower = less leverage | — | 4.13× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $74.6M | $156.8M | ||
| Q3 25 | $65.1M | $172.5M | ||
| Q2 25 | $65.4M | $172.9M | ||
| Q1 25 | $49.9M | $187.1M | ||
| Q4 24 | $49.5M | $199.9M | ||
| Q3 24 | $73.7M | $247.4M | ||
| Q2 24 | $63.7M | $250.6M | ||
| Q1 24 | $60.3M | $173.0M |
| Q4 25 | — | $4.0B | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | $3.7B | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | $1.3B | $976.8M | ||
| Q3 25 | $1.3B | $952.9M | ||
| Q2 25 | $1.3B | $896.0M | ||
| Q1 25 | $1.2B | $819.1M | ||
| Q4 24 | $1.1B | $767.3M | ||
| Q3 24 | $1.2B | $1.0B | ||
| Q2 24 | $1.1B | $988.1M | ||
| Q1 24 | $1.1B | $953.9M |
| Q4 25 | $1.7B | $5.3B | ||
| Q3 25 | $1.7B | $5.3B | ||
| Q2 25 | $1.7B | $5.2B | ||
| Q1 25 | $1.6B | $5.0B | ||
| Q4 24 | $1.6B | $4.8B | ||
| Q3 24 | $1.6B | $5.0B | ||
| Q2 24 | $1.6B | $4.8B | ||
| Q1 24 | $1.6B | $4.7B |
| Q4 25 | — | 4.13× | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 4.83× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $67.3M | $153.2M |
| Free Cash FlowOCF − Capex | — | $126.9M |
| FCF MarginFCF / Revenue | — | 26.8% |
| Capex IntensityCapex / Revenue | — | 5.5% |
| Cash ConversionOCF / Net Profit | 1.72× | 2.00× |
| TTM Free Cash FlowTrailing 4 quarters | — | $244.0M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $67.3M | $153.2M | ||
| Q3 25 | $65.6M | $81.6M | ||
| Q2 25 | $47.3M | $9.5M | ||
| Q1 25 | $36.5M | $45.3M | ||
| Q4 24 | $52.3M | $156.2M | ||
| Q3 24 | $51.3M | $45.9M | ||
| Q2 24 | $45.0M | $35.7M | ||
| Q1 24 | $33.4M | $51.0M |
| Q4 25 | — | $126.9M | ||
| Q3 25 | — | $75.6M | ||
| Q2 25 | — | $3.2M | ||
| Q1 25 | — | $38.3M | ||
| Q4 24 | — | $127.2M | ||
| Q3 24 | — | $39.7M | ||
| Q2 24 | — | $28.3M | ||
| Q1 24 | — | $44.1M |
| Q4 25 | — | 26.8% | ||
| Q3 25 | — | 16.4% | ||
| Q2 25 | — | 0.7% | ||
| Q1 25 | — | 9.7% | ||
| Q4 24 | — | 47.9% | ||
| Q3 24 | — | 10.8% | ||
| Q2 24 | — | 8.0% | ||
| Q1 24 | — | 13.4% |
| Q4 25 | — | 5.5% | ||
| Q3 25 | — | 1.3% | ||
| Q2 25 | — | 1.4% | ||
| Q1 25 | — | 1.8% | ||
| Q4 24 | — | 10.9% | ||
| Q3 24 | — | 1.7% | ||
| Q2 24 | — | 2.1% | ||
| Q1 24 | — | 2.1% |
| Q4 25 | 1.72× | 2.00× | ||
| Q3 25 | 1.63× | 1.09× | ||
| Q2 25 | 1.23× | 0.16× | ||
| Q1 25 | 0.98× | 0.97× | ||
| Q4 24 | 1.56× | — | ||
| Q3 24 | 1.52× | 1.50× | ||
| Q2 24 | 1.40× | 1.11× | ||
| Q1 24 | 1.15× | 2.19× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
BCPC
| Human Nutrition And Health | $166.1M | 63% |
| Animal Nutrition And Health | $61.2M | 23% |
| Specialty Products | $34.8M | 13% |
ECPG
Segment breakdown not available.
